Ruthenium-based Photoactive Metalloantibiotics
- PMID: 33882620
- DOI: 10.1111/php.13435
Ruthenium-based Photoactive Metalloantibiotics
Abstract
Antibiotic resistance is one of the world's most urgent public health problems. Antimicrobial photodynamic therapy (aPDT) is a promising therapy to combat the growing threat of antibiotic resistance. The aPDT combines a photosensitizer and light to generate reactive oxygen species to induce bacterial inactivation. Ruthenium polypyridyl complexes are significant because they possess unique photophysical properties that allow them to produce reactive oxygen species upon photoirradiation, which leads to cytotoxicity. These antimicrobial agents cause bacterial cell death by DNA and cytoplasmic membrane damage. This article presents a comprehensive review of photoactive antimicrobial properties of kinetically inert and labile ruthenium complexes, nanoparticles coupled photoactive ruthenium complexes, and photoactive ruthenium nanoparticles. Additionally, limitations of current ruthenium-based photoactive antimicrobial agents and future directions for the development of antibiotic-resistant photoactive antimicrobial agents are discussed. It is important to raise awareness for the ruthenium-based aPDT agents in order to develop a new class of photoactive metalloantibiotics capable of combating antibiotic resistance.
© 2021 American Society for Photobiology.
References
REFERENCES
-
- Centers for Disease Control and Prevention (2021). Available at: https://www.cdc.gov/drugresistance/biggest-threats.html. Accessed on 20 March 2021.
-
- Frei, A., J. Zuegg, A. G. Elliott, M. Baker, S. Braese, C. Brown, F. Chen, C. G. Dowson, G. Dujardin, N. Jung, A. P. King, A. M. Mansour, M. Massi, J. Moat, H. A. Mohamed, A. K. Renfrew, P. J. Rutledge, P. J. Sadler, M. H. Todd, C. E. Willans, J. J. Wilson, M. A. Cooper and M. A. T. Blaskovich (2020) Metal complexes as a promising source for new antibiotics. Chemical Science 11, 2627-2639.
-
- Kean, W. F. and I. R. Kean (2008) Clinical pharmacology of gold. Inflammopharmacology 16, 112-125.
-
- Jamieson, E. R. and S. J. Lippard (1999) Structure, recognition, and processing of cisplatin−DNA adducts. Chem. Rev. 99, 2467-2498.
-
- Reedijk, J. (1999) Why does cisplatin reach guanine-n7 with competing s-donor ligands available in the cell? Chem. Rev. 99, 2499-2510.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources